Velsera was formed in 2023 through the merger of Seven Bridges and Pierian, with a mission to accelerate the discovery, development, and delivery of life-changing insights in the pharmaceutical and diagnostic industries. The company provides AI-powered multimodal data harmonization and analytics software for drug discovery and development, as well as services for in vitro diagnostic (IVD) development, validation, and regulatory approval. Velsera also offers clinical NGS interpretation, reporting, and adoption solutions. With headquarters in Boston, MA, the company is expanding its teams across multiple countries to support the growing demand for its software and professional services in the life sciences sector.
Industry
Healthcare Technology
Company Size
51-200 employees
Founded
2023
Remote Policy
Hybrid
Beta · Sourced from candidate reports
Be the first to share your experience with Velsera.
Your reply helps other candidates know what to expect.
